Effect of the three-drug regimen of H. Pylori eradication with and without probiotics on the eradication treatment

Effect of the three-drug regimen of H. Pylori eradication with and without probiotics on the eradication treatment: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N344

Enrollment

150

Registered

2020-03-09

Start date

2018-09-23

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. Pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Amoxicillin capsule 1000 mg (manufactured by Dana Pharmaceuticals Co.) every 12 hours for 12 weeks, and Clarithromycin tablet 500 mg (manufactured by Dana Pharmaceu

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years, H. pylori infection,

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding, Gastric cancer, Kidney or liver failure, History of gastric surgery, Previous history of Helicobacter pylori treatment,

Design outcomes

Primary

Measure	Time frame
H. Pylori eradication. Timepoint: 12 weeks after the intervention. Method of measurement: By respiratory urease test.	—

Secondary

Measure	Time frame
Assessing gastrointestinal complications. Timepoint: 12 weeks after the intervention. Method of measurement: By taking history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Rahkoy

Hamedan University of Medical Sciences

zahra.rahkoy@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026